Amelioration of beryllium induced alterations in hepatorenal biochemistry and ultramorphology by co-administration of tiferron and adjuvants.
Influence of adjuvants i.e., alpha-tocopherol (25 mg/kg, p.o.) and piperine (10 mg/kg, p.o.) on therapeutic potential of chelator tiferron (300 mg/kg, i.p.) was evaluated to encounter toxicogenic events of beryllium exposure. Albino rats were exposed to beryllium nitrate (1 mg/kg, i.p.) daily for 28 days followed by treatment of aforesaid therapeutic agents for 5 consecutive days. Results were considered to be significant at p < or =0.01 and p < or =0.05. Exposure to beryllium increased its concentration in liver, kidney and serum causing significant alterations in the activity of CYP-450 2E1 system, microsomal lipid peroxidation and protein; alkaline phosphtase, lactate dehydrogenase, gamma-glutamyl transpeptidase, bilirubin, creatinine and urea in serum; activity of acid phosphatase, alkaline phosphatase, adenosine triphosphatase, glucose-6-phosphatase and succinic dehydrogenase in liver and kidney. Beryllium exposure also induced severe alterations in histopathology and ultramorphology of liver and kidney proving its toxic consequences at cellular level. Tiferron along with adjuvants dramatically reversed alterations of all variables more towards control rather than individual treatment. Study concluded that tiferron in combination with alpha-tocopherol and piperine respectively was beneficial in diluting beryllium induced systemic toxicity; however, combination of tiferron and piperine presented more pronounced therapeutic potential.
Nirala
Satendra Kumar
SK
School of Studies in Zoology, Jiwaji University, Gwalior, 474011, India. satendrak75@rediffmail.com
Bhadauria
Monika
M
Mathur
Ramesh
R
Mathur
Asha
A
D000277:Adjuvants, Pharmaceutic; D000470:Alkaloids / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D052117:Benzodioxoles / Q000494:pharmacology* / Q000627:therapeutic use; D001608:Beryllium / Q000633:toxicity*; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006530:Hepatorenal Syndrome / Q000628:therapy; D007668:Kidney / Q000187:drug effects*; D008099:Liver / Q000166:cytology / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D053284:Polyunsaturated Alkamides / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D024502:alpha-Tocopherol / Q000494:pharmacology*
D000277:Adjuvants, Pharmaceutic; D000470:Alkaloids; D052117:Benzodioxoles; D002614:Chelating Agents; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D024502:alpha-Tocopherol; D001608:Beryllium; C008922:piperine